El óxido nítrico desempeña múltiples acciones fisiológicas en el sistema cardiovascular. Las alternaciones en la ruta del óxido nítrico ejercen un papel importante en el origen y el desarrollo de las enfermedades cardiovasculares. Desde el punto de vista terapéutico, la modulación de la ruta del óxido nítrico representa una diana muy interesante.
En el artículo se revisan las múltiples aproximaciones farmacológicas para actuar sobre la ruta del óxido nítrico. De dichas aproximaciones, se otorga una atención especial a los donadores de óxido nítrico. Entre los donadores de óxido nítrico destacan LA-419 (en desarrollo para la angina crónica estable) y LA-816 (en desarrollo como antitrombótico).
Palabras clave
Óxido nítrico
Donador de óxido nítrico
Terapia
Este artículo solo puede leerse en
pdf
Bibliografía
[1.]
R.F. Furchgott, J.V. Zawadzki.
The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine.
Nature, (1980), 288 pp. 373-376
[2.]
R.M.J. Palmer, A.G. Ferrige, S. Moncada.
Nitric oxide accounts for the biological activity of endothelium-derived relaxing factor.
Nature, (1987), 327 pp. 524-526
[3.]
R.M.J. Palmer, D.S. Ashton, S. Moncada.
Vascular endothelial cells syntheseze nitric oxide from L-arginine.
Nature, (1988), 333 pp. 664-666
[4.]
EMEA. Product Information INOmax EMEA-H-337-I-0007-PI. Disponible en: www.emea.ev.int/humandocs/Humans/EPAR/inomax/inomaxM.htm
[6.]
A. Chung, S.M. Wildhirt, S. Wang, A. Koshal, M.W. Radomski.
Combined administrtion of nitric oxide gas and iloprost during cardiopulmonary bypass reduces platelet dysfinction: a pilos clinical study.
J Thorac Cardiovasc Surg, (2005), 129 pp. 782-790
[7.]
FDA Approves BiDil Heart Failure Drug for Black Patients. FDA News P05-32, June 23, 2005.
[8.]
M.A. Branca.
BiDil raises questions about race as a marker.
Nat Rev Drug Discov, (2005), 4 pp. 615-616
[9.]
P. Carson, S. Ziesche, G. Johnson, J.N. Cohn.
Racial differences in response to therapy for heart failure:analysis of the vasodilatorheart failure trials. Vasodilator-Heart Failure Trial Study Group.
J Card Fail, (1999), 5 pp. 178-187
[10.]
A.L. Taylor, S. Ziesche, C. Yancy, R D’Agostino Jr, K. Ferdinand, M. Taylor, et al.
African-American Heart Failure Trial Investigators. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure.
N Engl J Med, (2004), 351 pp. 2049-2057
[12.]
J.L. Wallace, M.N. Muscara, W. McKnight, M. Dicay, P. Del Soldato, G. Cirino.
In vivo antithrombotic effect of a nitric oxide-releasing aspirin derivative, NCX-4016.
Thromb Research, (1999), 93 pp. 43-50
[13.]
International patent number WO 00/20420. Intellectual property world organization. Derivatives os isosorbid mononitrate as vasodilator agents with reduced tolerance. Disponible en: www.wipo.int/ipdl/es/search/pct/search-struct.jsp
[14.]
Y. Hirata, H. Miyai, Y. Mabuchi, K. Aisake.
Effect of JTV-506, a novel vasodilator, on experimental angina model in rats.
J Cardiovasc Pharmacol, (1998), 31 pp. 322-326
[15.]
M.R. Hernández, R. Tonda, G. Arderiu, M. Pino, M. Serradell, G. Escolar.
Antithrombotic effect of a new nitric oside donor (LA419) on experimental thrombogenesis.
Eur J Clin Invest, (2005), 35 pp. 337-342
[16.]
G. Vilahur, E. Segeles, L. Casani, K. Badimon.
A novel anti-ischemic nitric oxide donor inhibits thrombosis without modifying haemodynamic parameters.
Thromb Haemost, (2004), 91 pp. 1035-1043
[17.]
A.O. Maree, D. Cox.
Thrombosis and nitric oxide donor drugs.
Thromb Haemost, (2004), 91 pp. 848-850
[18.]
A.G. Herman, S. Moncada.
Therapeutic potential of nitric oxide donors in the prevention and treatment of atherosclerosis.
Eur Heart J, (2005), 26 pp. 1945-1955
[19.]
P.J. Mason, J.E. Freeman, A.K. Jacobs.
Aspirin resitance: current concepts.
Rev Cardiovasc Med, (2004), 5 pp. 156-163
[20.]
T.A. Nguyen, J.G. Diodati, C. Pharand.
Resistance to clopidogrel: a review of the evidence.
J Am Coll Cardiol, (2005), 45 pp. 1157-1164
[21.]
R.M. Gowda, I.A. Khan, B.C. Vasavada, T.J. Scchi.
Therapeutics of platelet glycoprotein IIb/IIIa receptor antagonism.
Am J Ther, (2004), 11 pp. 302-307
[22.]
M.W. Radomski, T. Zakar, E. Salas.
Nitric oxide in platelets.
Methods Enzymol, (1996), 269 pp. 88-107
[23.]
M.W. Radomski, S. Moncada.
The biological and pharmacological role of nitric oxide in platelet function.
Adv Exp Med Biol, (1993), 344 pp. 251-264
[24.]
International patent number WO 00/44714. Intellectual property world organization. S-nitrosothiols as agents for the treatment of circulatory dysfunctions. Disponible en: www.wipo.int/ipdl/es/search/pct/search-struct.jsp
[25.]
G. Vilahur, E. Segáles, E. Salas, L. Badimon.
Effects of a novel platelet nitric oxide donor (LA816), aspirin, clopidogrel, and combined therapy in inhibiting flow- and lesion-dependent thrombosis in the porcine ex vivo model.
Circulation, (2004), 110 pp. 1686-1693
Copyright ©
2006. Sociedad Española de Cardiología